MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Regional Analysis

To learn more about this report, request sample copy

North America remains the dominant region in the global minimal residual disease testing market and is anticipated to hold 34.5% of the market share in 2024. North America has established itself as the leading region in the global minimal residual disease testing market. The presence of some of the top pharmaceutical and biotechnology companies along with advanced healthcare infrastructure and high healthcare spending have fueled market growth. The U.S. accounts for the largest share due to the growing adoption of MRD testing in clinical trials and patient monitoring practices. Several hospitals and laboratories in the country are well-equipped with modern testing technologies and skilled professionals to perform these tests routinely.

Asia Pacific is recognized as the fastest-growing market for MRD testing globally. The growth can be attributed to improving healthcare infrastructure, expanding patient pool of hematological cancers, and growing medical tourism across India, China, and other countries. Various initiatives by governments to promote localization of production are also encouraging international companies to tap into opportunities. While the market is still in the growth phase, improving purchasing power and demand for advanced diagnostic technologies will likely aid regional expansion in the coming years.